EUTOS Score for Chronic Myelogenous Leukaemia
Predicts achievement of complete cytogenetic response (CCyR) at 18 months in CML treated with imatinib.
Score interpretation
EUTOS ≤ 87: Low risk. 5-year progression-free survival 90% on imatinib (Hasford 2011).
→ Standard imatinib dosing. Monitor per European LeukemiaNet (ELN) milestones.
EUTOS > 87: High risk. 34% did not reach complete cytogenetic response at 18 months on imatinib; 5-year progression-free survival 82% (Hasford 2011).
→ Consider 2nd-generation TKI upfront. Enrol in clinical trial if possible. Close monitoring of milestones.
Interpretation bands for the EUTOS Score. Apply clinical judgement and local guidance.
References
- Hasford J et al. Predicting complete cytogenetic remission and subsequent progression-free survival in 2060 patients with CML on imatinib treatment. Blood. 2011;118(3):686-692.
Related
Curated clinical cross-links plus same-class fallbacks.
- Omalizumab (Dermatology — Chronic Urticaria) · Anti-IgE Monoclonal Antibody
- Fentanyl Transdermal Patch (Elderly Chronic Pain) · Opioid Analgesic — Transdermal Patch
- Morphine Slow-Release (Elderly Chronic Pain) · Opioid Analgesic — Modified-Release Oral
- Imatinib · Tyrosine kinase inhibitor (BCR-ABL)
- Methyldopa (Chronic Hypertension in Pregnancy) · Centrally Acting Antihypertensive
- Propranolol (Burns — Hypermetabolic Response) · Beta-Blocker — Burns Hypermetabolism
- Major Haemorrhage / Massive Transfusion · BCSH; RCOA; RCEM; RCS — BCSH Guidelines
- Anaemia Investigation · BSH / NICE
- Splenomegaly Workup · BSH; BMJ Best Practice
- Deep Vein Thrombosis Diagnosis and Treatment · NICE CG144 / NICE NG158
- Sickle Cell Crisis · BSH 2021 / BCSH
- Neutropenic Sepsis · NICE CG151 2012 / ESMO
Decision support only — verify against a current formulary, NICE, or your local guideline before clinical use.
